Testing effectiveness (Phase 2)Study completedNCT00639002
What this trial is testing
Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Who this might be right for
Multiple Myeloma
Incyte Corporation 13